Creatine on a GLP-1: What the Evidence Says

Of all the supplements people ask about while losing weight on a GLP-1, creatine arrives with the deepest research file. Creatine monohydrate is one of the most studied supplements in sports nutrition, with decades of trials behind it, and the questions people bring to it here are usually sensible ones about holding onto muscle while the scale falls. What the general literature does not come with is any experience in people taking these medicines, because it was never built for them.

So this article does three jobs. It summarizes the lean mass evidence, with the numbers the studies actually produced. It covers the two questions specific to life on a GLP-1 that the creatine literature barely mentions: what loading does to the scale, and what it does to a kidney panel. And it states the honest limits of carrying research across from other populations. It recommends nothing in either direction.

What the studies use

The International Society of Sports Nutrition position stand describes two common approaches. The first is a loading phase of 0.3 grams per kilogram per day for 5 to 7 days, split into 3 to 4 doses, which works out to roughly 20 grams a day for a 70 kilogram person, followed by 3 to 5 grams a day. The second skips the loading step entirely: 3 to 5 grams a day from the start, which saturates muscle in about 3 to 4 weeks. Those are the regimens the research used, and they are reported here as exactly that. Whether any amount makes sense for any reader is a question for their clinician or a dietitian, and the question stands whether the answer turns out to be yes or no.

The difference between the two approaches is speed. Loading reaches saturation in under a week, the steady low dose takes about a month, and the end state is the same muscle store either way. The loading route is also the one that produces the scale event described below, simply because it front loads the intake into a few days. People who dislike the idea of a fast step on the scale sometimes prefer the slower route for that reason alone, which is a preference about data, not a conclusion about results.

What the lean mass evidence shows

The most useful summary for people losing weight is a meta-analysis of creatine plus resistance training in older adults. It pooled 22 studies and 721 participants, with mean ages across studies ranging from 57 to 70, training 2 to 3 days a week for 7 to 52 weeks. On average, the creatine groups gained 1.37 kg more lean tissue mass than the placebo groups, with a 95 percent confidence interval of 0.97 to 1.76 kg.

The sentence that usually gets dropped matters most: the training was doing the work. That gain is the difference between training with creatine and training without it, not the difference between taking creatine and doing nothing. The floor of the whole subject is resistance training and adequate protein, which have their own guides in Two Days of Strength Training: The GLP-1 Muscle Insurance and Protein Goals on GLP-1s: Protecting Muscle While Losing Weight. Creatine is a question people ask on top of that floor, and the evidence supports the floor first.

GLP 1 Tracker AppWeight trend, protein, water and doses in one private place, so a step on the scale becomes a line on a chart instead of a bad night. Get the app

What loading does to the scale

Here is the first thing the general creatine literature barely mentions, because outside a weight loss context nobody cares. Loading creatine typically adds roughly 1 to 3 kg of scale weight over the first 5 to 7 days. The gain is water: creatine enters muscle on a sodium dependent transporter, and water follows it inward. It is not fat, and it is not the medicine failing.

On a GLP-1, where people watch a trend line closely, a jump of 2 kg in a week is precisely the shape of a regain scare. It arrives fast, it sits there, and it has nothing to do with fat. Anyone starting creatine while tracking weight should expect the step and know what it is before it happens, because a known water shift reads very differently from an unexplained reversal. Reading the trend rather than the single reading is the skill that carries it, covered in How to Read a Weight Trend Line, and how often to step on the scale at all is its own question in Daily or Weekly Weigh-Ins on a GLP-1? Both Work, Differently.

The step also has a shape, and the shape is what saves the readout. It arrives inside the loading window and then stops, because it tracks the filling of the muscle store rather than anything accumulating. A regain, by contrast, climbs. On a chart the difference is a step followed by a flat line versus a slope, and knowing which one you are looking at is most of the work of not panicking. The water sits there while the store stays full; the step is not the opening move of a trend.

What it does to a kidney panel

The second GLP-1 specific point is the more important one. Systematic reviews of creatine and kidney function keep finding the same pattern: creatine raises measured serum creatinine and lowers eGFR when the eGFR is estimated from creatinine, while measures that assess filtration more directly show no change, and urea, albuminuria and proteinuria do not change either. The reviews read that pattern as creatine metabolism showing up in the test rather than as kidney injury.

The practical consequence is the reason this article exists. A clinician reading a kidney panel needs to know the person takes creatine. Kidney function is something clinicians watch on these medicines, and a creatinine number nudged upward by a supplement can look like something it is not. What any individual's numbers mean, in either direction, belongs entirely to the clinician who ordered them; the wider subject of labs on these medicines sits in Blood Work on a GLP-1: Numbers Worth Keeping and GLP-1s and Your Kidneys: Why Dehydration Is the Risk.

The honest limits

Three of them belong on the page. The creatine literature was not built in people taking GLP-1 medications, so every finding above is carried over from other populations, and carrying findings across populations is an assumption, not a result. In the United States, supplements are not reviewed by the FDA for effectiveness before they go on sale, and what is in the tub is the manufacturer's responsibility; independent third-party testing programs exist for people who want that check on a product. And anyone with kidney disease, anyone taking medicines that affect the kidneys, and anyone unsure should ask their clinician or a dietitian before adding a supplement.

There is also a smaller, more personal limit worth naming. On a suppressed appetite, the ordinary food sources of protein feel like work, and supplements of every kind start looking like insurance. That instinct is exactly why the clinician conversation matters more here rather than less: the question is never whether a powder is good in the abstract, but whether it fits the specific person, their kidneys, their medicines and their lab schedule.

That is the entire conclusion this article will draw, and it is deliberately a small one. The evidence for creatine alongside training is real, the scale jump is water, the creatinine bump is a test artifact worth a clinician knowing about, and none of it was measured in people on these medicines. The decision itself sits where supplement decisions always sit, with the people who can see your history, which is where it already belonged.